Imfinzi, mainly a lung cancer treatment, was granted accelerated approval for the bladder cancer indication in 2017, and the withdrawal does not impact markets outside the United States, the company said.
The treatment failed the main goal of a late-state trial last year and the decision was based in consultation with U.S. authorities, the company said.
"While the withdrawal in previously treated metastatic bladder cancer is disappointing, we respect the principles FDA set out when the accelerated approval pathway was founded," Dave Fredrickson, executive vice president of the company's oncology business division, said in a statement.
Imfinzi belongs to the immunotherapy class of treatments that boost the body's own defences to fight cancer.
AstraZeneca also said other U.S. indications for the drug, which brought in $2.04 billion in global revenue last year, were not affected by the withdrawal, adding that it was notifying healthcare providers of the update.
By Reuters Staff
Posted on
Previous Article
« Letter from the Editor Next Article
Algorithm uses routine blood tests to detect advanced liver disease »
« Letter from the Editor Next Article
Algorithm uses routine blood tests to detect advanced liver disease »
Related Articles
September 17, 2020
First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel
July 22, 2022
Prostate cancer treatments reduce quality of life

© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com